Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion [19]

Leukemia

Volumn 21, Issue 4, 2007, Pages 848-851

  Huang, X J ^a   Zhao, X Y ^a   Liu, D H ^a   Liu, K Y ^a   Xu, L P ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; KIR PROTEIN; LIGAND; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT; SIMUSTINE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; COMBINATION CHEMOTHERAPY; GENETIC INCOMPATIBILITY; HIGH RISK PATIENT; HLA SYSTEM; HLA TYPING; HUMAN; KAPLAN MEIER METHOD; LETTER; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; T CELL DEPLETION; THROMBOCYTE COUNT;

EID: 33847612506     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404566     Document Type: Letter

References (8)

1. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
2. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA et al. The effect of KIR Ligand Incompatibility on the outcome of unrelated donor transplantation: A report from the center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 2006; 12: 876-884.
3. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819.
4. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291-297.
5. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370-4376.
6. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2006, doi 10.1016/ j.trim.2006.10.002.
7. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P et al. Determinants of Antileukemia Effects of Allogeneic NK Cells. J Immunol 2004; 172: 644-650.
8. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19: 1446-1451.